18 names are moving together; 50% are participating in the current session.
Observed intraday paths are not available for this group yet.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| INR | Infinity Natural Resources, Inc | Energy | -1.4% | Group member |
| RAPP | Rapport Therapeutics, Inc. | Healthcare | +1.8% | Group member |
| GPOR | Gulfport Energy Corporation | Energy | -1.9% | Group member |
| ABUS | Arbutus Biopharma Corporation | Healthcare | -1.2% | Group member |
| ACHC | Acadia Healthcare Company, Inc. | Healthcare | +3.5% | Group member |
| NTLA | Intellia Therapeutics, Inc. | Healthcare | +2.2% | Group member |
| RSI | Rush Street Interactive, Inc. | Consumer Cyclical | -2.1% | Group member |
| BEAM | Beam Therapeutics Inc. | Healthcare | -0.3% | Group member |
| PMAX | Powell Max Limited | Financial Services | -6.1% | Group member |
| OCUL | Ocular Therapeutix, Inc. | Healthcare | -1.8% | Group member |
| KRYS | Krystal Biotech, Inc. | Healthcare | -6.6% | Most structurally connected |
| COR | Cencora, Inc. | Healthcare | -1.3% | Group member |
| BIYA | Baiya International Group Inc. | Technology | +1.3% | Group member |
| DRUG | Bright Minds Biosciences Inc. | Healthcare | +0.3% | Group member |
| BIOA | BioAge Labs, Inc. | Healthcare | +4.7% | Group member |
| QTTB | Q32 Bio Inc. | Healthcare | -13.4% | Group member |
| TNK | Teekay Tankers Ltd. | Energy | +2.1% | Group member |
| FDMT | 4D Molecular Therapeutics, Inc. | Healthcare | +3.5% | Group member |
Cohort
18 namesParticipation
50% this sessionObserved history
1 daily buildsFiling coverage
14/18 membersproduct pipeline / R&D affecting expense
“The increase in research and development expenses was primarily attributable to: • a net increase of $0.9 million in unallocated materials and other support costs for our pipeline products; and • a net increase of $0.8 million in R&D payroll and manufacturing costs driven by the timing of production runs across our product candidates and programs, mainly due to an increase in KB111, KB407, and KB803, partially offset by a decrease in B-VEC.”
KRYS 10-Q
credit / rates affecting interest expense
“Other income (loss) The components of our other income (loss) are summarized in the following table: Three Months Ended March 31, 2026 2025 (in thousands) Interest income $ 815 $ 1,197 Interest expense (17) (28) Foreign exchange (loss) gain (11) 4 Total other income $ 787 $ 1,173 Interest income The decrease in interest income for the three months ended March 31, 2026 compared to the same period in 2025 was due primarily to less interest earned on our cash and investment balances due to a lower average balance and a general decrease in market interest rates.”
ABUS 10-Q
restructuring affecting expense
“Modification associated with restructuring During the year ended December 31, 2025, the Company recognized $ 2.5 million of expense related to the modification of stock options for employees who were terminated as a result of the restructuring (Note 16).”
ABUS 10-K
Biotech and Energy can stay leader-led if ABUS and the next software names fail to join while KRYS keeps moving.
No high-confidence filing-linked non-members are available for this group yet.
Historical cohort observations are not available yet.